Experts say a key factor determining the dynamics between Brussels and Beijing is Europe’s underlying concern over China’s ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

Every Friday, we recap highlights of the news from China. The Dalai Lama’s succession dominated headlines in recent days, ...